25 April 2018 - - Aachen, Germany-based pharmaceutical company Grünenthal GmbH has appointed Philip Just Larsen as chief scientific officer and member of the corporate executive board,.
He will assume leadership of Grünenthal's research and development organization on 1 July 2018.
Currently, Philip holds the role of global head of diabetes research and translational medicine and chief scientific officer at Sanofi's German Hub in Frankfurt.
Philip is a senior leader with extensive experience in drug discovery and development including successful transition into the clinic.
He is a Medical Doctor trained in internal medicine and neurology, has been awarded a PhD in Neuroscience/Endocrinology and held international management positions in research and development at Eli Lilly and Novo Nordisk.
Entrepreneurial, science-based Grünenthal specializes in pain, gout, and inflammation. It is a fully integrated research and development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients.
Independent, family-owned Grünenthal is present in 32 countries with affiliates in Europe, Latin America, and the US.
Its products are sold in more than 155 countries and the company employs roughly 5,200 employees worldwide.